ATE325187T1 - Bildung, konzentration und effizienter transfer von vsv-g pseudotypisierten retroviralen vektoren - Google Patents

Bildung, konzentration und effizienter transfer von vsv-g pseudotypisierten retroviralen vektoren

Info

Publication number
ATE325187T1
ATE325187T1 AT94919349T AT94919349T ATE325187T1 AT E325187 T1 ATE325187 T1 AT E325187T1 AT 94919349 T AT94919349 T AT 94919349T AT 94919349 T AT94919349 T AT 94919349T AT E325187 T1 ATE325187 T1 AT E325187T1
Authority
AT
Austria
Prior art keywords
vectors
retroviral
cells
present application
cell line
Prior art date
Application number
AT94919349T
Other languages
English (en)
Inventor
Jane C Burns
Jiing-Kuan Yee
Theodore Friedmann
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE325187T1 publication Critical patent/ATE325187T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • C12N2740/13062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Optical Radar Systems And Details Thereof (AREA)
  • Inert Electrodes (AREA)
  • Road Paving Structures (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Traffic Control Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT94919349T 1993-06-04 1994-06-03 Bildung, konzentration und effizienter transfer von vsv-g pseudotypisierten retroviralen vektoren ATE325187T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7320993A 1993-06-04 1993-06-04
US08/104,804 US5512421A (en) 1991-02-19 1993-08-10 Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors

Publications (1)

Publication Number Publication Date
ATE325187T1 true ATE325187T1 (de) 2006-06-15

Family

ID=26754237

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94919349T ATE325187T1 (de) 1993-06-04 1994-06-03 Bildung, konzentration und effizienter transfer von vsv-g pseudotypisierten retroviralen vektoren

Country Status (7)

Country Link
US (2) US5512421A (de)
EP (1) EP0702717B1 (de)
JP (1) JP3655307B2 (de)
AT (1) ATE325187T1 (de)
AU (1) AU686181B2 (de)
DE (1) DE69434724T2 (de)
WO (1) WO1994029440A1 (de)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333471T2 (de) * 1992-11-09 2005-02-24 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Erzielbare vektorenpartikel
CA2194488A1 (en) * 1994-08-05 1996-02-15 Tod Paul Holler Method of using transdominant negative retroviral integrase in the treatment of retroviral infection
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
AU4608096A (en) * 1994-12-30 1996-07-24 Chiron Corporation Production and administration of high titer recombinant retroviruses
US6117681A (en) * 1995-03-29 2000-09-12 Bavarian Nordic Research Inst. A/S Pseudotyped retroviral particles
US5750396A (en) * 1995-05-08 1998-05-12 St. Judes Children's Research Hospital Stable virus packaging cell lines
US5770720A (en) * 1995-08-30 1998-06-23 Barnes-Jewish Hospital Ubiquitin conjugating enzymes having transcriptional repressor activity
US5780448A (en) * 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
EP0859856A2 (de) * 1995-11-08 1998-08-26 Whitehead Institute For Biomedical Research Stabile verpackungszellinie, die pseudotyp-retroviren produziert
JP2000502261A (ja) * 1995-12-29 2000-02-29 カイロン コーポレイション 毒性タンパク質発現ウイルスおよびプロデューサー細胞株
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
FR2747046B1 (fr) * 1996-04-05 1998-06-19 Univ Paris Curie Nouveaux vaccins issus de plasmovirus
US6133027A (en) * 1996-08-07 2000-10-17 City Of Hope Inducible expression system
US5739018A (en) * 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors
JPH1080274A (ja) * 1996-09-06 1998-03-31 Hirofumi Hamada 核移行シグナルを結合したテトラサイクリン・トランスアクチベーター
US6818209B1 (en) * 1998-05-22 2004-11-16 Oxford Biomedica (Uk) Limited Retroviral delivery system
US20070213290A1 (en) * 1996-10-17 2007-09-13 Kingsman Alan J Neurite regeneration
GB2337520B (en) * 1998-05-22 2000-06-14 Oxford Biomedica Ltd Delivery system
EP0839913B1 (de) * 1996-11-04 2006-06-21 Ottawa Health Research Institute Verfahren zur Expression von Polypeptide in Fishen durch wässerung in DNS enthaltende Lösung
CN1059599C (zh) * 1996-12-27 2000-12-20 中国科学院水生生物研究所 蛙病毒疫苗
US6080912A (en) * 1997-03-20 2000-06-27 Wisconsin Alumni Research Foundation Methods for creating transgenic animals
CA2285937C (en) * 1997-04-10 2010-12-14 Frederick L. Hall Modified proteins which bind extracellular matrix components
AU2560999A (en) * 1998-01-21 1999-08-09 Regents Of The University Of Michigan, The Targeting gene transfer vectors to certain cell types by pseudotyping with viralglycoprotein
US6171862B1 (en) 1998-03-31 2001-01-09 The Regents Of The University Of California Transfection in serum-containing media
US20060292121A1 (en) * 1998-04-29 2006-12-28 Hall Frederick L Retroviral vectors including modified envelope escort protein
US7078483B2 (en) * 1998-04-29 2006-07-18 University Of Southern California Retroviral vectors including modified envelope escort proteins
US6448390B1 (en) 1998-05-20 2002-09-10 The University Of Tennessee Research Corporation Stable envelope proteins for retroviral, viral and liposome vectors and use in gene drug therapy
AU5465899A (en) * 1998-08-04 2000-02-28 Purdue Research Foundation Pseudotyped retroviruses and stable cell lines for their production
US7033595B1 (en) 1998-08-04 2006-04-25 Purdue Research Foundation Pseudotyped retroviruses and stable cell lines for their production
GB9904905D0 (en) * 1999-03-03 1999-04-28 Oxford Biomedica Ltd Cells
EP1173551A2 (de) * 1999-04-23 2002-01-23 Centre for Translational Research in Cancer Pseudotypisierte retrovirale vektoren zur gentherapie gegen krebs
ES2288473T3 (es) * 1999-05-18 2008-01-16 Dnavec Research Inc. Vector de virus deficiente en el gen de la envoltura de paramyxoviridae.
US6518481B1 (en) * 1999-08-12 2003-02-11 Exelixis, Inc. Universal markers of transgenesis
US20030224415A1 (en) * 2001-06-29 2003-12-04 Gala Design, Inc. Selection free growth of host cells containing multiple integrating vectors
AU2001271614B2 (en) 2000-07-03 2007-05-31 Catalent Pharma Solutions, Llc Host cells containing multiple integrating vectors
US20020106729A1 (en) * 2000-07-03 2002-08-08 Bleck Gregory T. Expression vectors
US20040235173A1 (en) * 2000-07-03 2004-11-25 Gala Design, Inc. Production of host cells containing multiple integrating vectors by serial transduction
US6627442B1 (en) 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
WO2002044394A2 (en) * 2000-11-29 2002-06-06 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
JP2002176880A (ja) * 2000-12-12 2002-06-25 Kanegafuchi Chem Ind Co Ltd 効率的な遺伝子導入鳥類の作製法及びそれによって得られる遺伝子導入鳥類
US7141649B2 (en) * 2001-01-26 2006-11-28 Vanderbilt University Mosquito arrestin 2 polypeptides
US7314723B2 (en) * 2001-01-26 2008-01-01 Vanderbilt University Method of identifying chemical agents which stimulate odorant receptors of sensory neurons
US7166699B2 (en) * 2001-01-26 2007-01-23 Vanderbilt University Mosquito arrestin 1 polypeptides
US20030026791A1 (en) * 2001-03-27 2003-02-06 Laurent Humeau Conditionally replicating vectors for inhibiting viral infections
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
JP4354814B2 (ja) 2001-09-29 2009-10-28 ヨンセイ ユニバーシティ 改善された疾患治療効果を有する組換えアデノウィルス及びそれを含む薬剤学的組成物
WO2003102219A2 (en) * 2002-06-04 2003-12-11 Purdue Research Foundation Improved pseudotyped retroviruses
US20040038304A1 (en) * 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US7384738B2 (en) * 2002-03-28 2008-06-10 Bremel Robert D Retrovirus-based genomic screening
CA2498297A1 (en) * 2002-09-09 2004-03-18 University Of Tennessee Research Foundation Recombinatant mutants of rhabdovirus and methods of use thereof
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
ATE513471T1 (de) * 2003-04-21 2011-07-15 Epeius Biotechnologies Corp Verfahren und zusammensetzungen zur behandlung von erkrankungen
US20090123428A1 (en) * 2003-04-21 2009-05-14 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
EP1624899B1 (de) * 2003-05-05 2010-11-17 VIRxSYS Corporation Erhöhte transduktion mit abc-transportersubstratenhemmern
PT1629004E (pt) * 2003-06-05 2008-11-14 Wyeth Corp Composições imunogénicas compreendendo vectores do replicão do vírus da encefalite equina venezuelana e antigénios proteicos de paramixovírus
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
WO2005038035A2 (en) * 2003-10-15 2005-04-28 University Of Iowa Research Foundation Methods for producing and using in vivo pseudotyped retroviruses
EP1690933B1 (de) * 2003-11-17 2013-04-24 Eisai R&D Management Co., Ltd. Herg-kanal exprimierende zelle
US7135339B2 (en) * 2003-11-20 2006-11-14 University Of Iowa Research Foundation Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)
US20050221429A1 (en) * 2004-01-16 2005-10-06 Cardinal Health Pts, Llc Host cells containing multiple integrating vectors comprising an amplifiable marker
JP5546716B2 (ja) 2004-09-29 2014-07-09 タカラバイオ株式会社 レトロウイルスベクター産生用細胞
CN101238218A (zh) * 2005-05-20 2008-08-06 维克西斯公司 初级细胞的转导
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
WO2008066658A2 (en) * 2006-11-03 2008-06-05 The Trustees Of Princeton University Engineered cellular pathways for programmed autoregulation of differentiation
DE102006061184A1 (de) 2006-12-22 2008-06-26 Fresenius Medical Care Deutschland Gmbh Verfahren zum Primen eines Blutschlauchsatzes
WO2010105020A2 (en) * 2009-03-13 2010-09-16 Boyce Thompson Institute For Plant Research Baculoviruses with enhanced virion production and a method for the production of baculoviruses
WO2009014878A2 (en) * 2007-07-06 2009-01-29 Boyce Thompson Institute For Plant Research Baculoviruses with enhanced virion production and a method for the production of baculoviruses
US8703469B2 (en) 2007-07-06 2014-04-22 Boyce Thompson Institute For Plant Research Baculoviruses with enhanced virion production and a method for the production of baculoviruses
EP2271754A4 (de) * 2008-03-28 2013-01-16 Virxsys Corp Auf lentivirus basierende immunogene vektoren
US20100076061A1 (en) * 2008-04-30 2010-03-25 University Of Iowa Research Foundation Repeated administration of lentiviral vectors to respiratory cells
ES2618851T3 (es) 2008-06-18 2017-06-22 Oxford Biomedica (Uk) Limited Purificación de vectores retrovirales
JP5965392B2 (ja) 2010-05-28 2016-08-03 オックスフォード バイオメディカ （ユーケー） リミテッド 脳へのレンチウイルスベクターの送達
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
GB201118636D0 (en) 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
GB201202516D0 (en) 2012-02-13 2012-03-28 Ucl Business Plc Materials and methods relating to packaging cell lines
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
EP3663405B8 (de) 2013-06-11 2024-10-30 Takara Bio USA, Inc. Proteinangereicherte mikrovesikel und verfahren zur herstellung und verwendung davon
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
EP3313420B1 (de) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Verfahren und zusammensetzungen in bezug auf hämatopoetische stammzellenexpansion, -anreicherung und -pflege
CN115925910A (zh) 2016-03-09 2023-04-07 马萨诸塞大学 经修饰的hiv-1用于产生完全人抗体的用途
US20190119642A1 (en) 2016-03-15 2019-04-25 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
CN110785419B (zh) 2017-04-12 2024-03-01 博雅缉因（北京）生物科技有限公司 芳烃受体拮抗剂及其用途
US20190314407A1 (en) 2017-10-31 2019-10-17 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
WO2019089833A1 (en) 2017-10-31 2019-05-09 Magenta Therapeutics Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
EP3696272A1 (de) 2017-12-22 2020-08-19 Oxford BioMedica (UK) Limited Retroviraler vektor
AU2019205262A1 (en) 2018-01-03 2020-07-23 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
CN113260609A (zh) 2018-09-04 2021-08-13 美真达治疗公司 芳烃受体拮抗剂及其使用方法
CA3133188A1 (en) 2019-03-10 2020-09-17 Oxford Biomedica (Uk) Limited Gene therapy compositions and methods for treating parkinson's disease
US20230002777A1 (en) 2019-11-12 2023-01-05 Oxford Biomedica (Uk) Limited Production System
WO2021160993A1 (en) 2020-02-13 2021-08-19 Oxford Biomedica (Uk) Limited Production of lentiviral vectors
CN115667534A (zh) 2020-03-13 2023-01-31 牛津生物医学（英国）有限公司 慢病毒载体
GB202007199D0 (en) 2020-05-15 2020-07-01 Oxford Biomedica Ltd Viral vector production
GB202017725D0 (en) 2020-11-10 2020-12-23 Oxford Biomedica Ltd Method
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
GB202114528D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114534D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Novel viral regulatory elements
GB202117844D0 (en) 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
FR2619012B1 (fr) * 1987-08-07 1989-12-22 Pasteur Institut Vaccins dont l'epitope caracteristique est incorpore dans une proteine de picornavirus, notamment de poliovirus
EP0441897A4 (en) * 1988-11-14 1992-06-24 Us Health Parvovirus capsids
JPH04504361A (ja) * 1989-04-05 1992-08-06 ノバセル　コーポレイション 感染性標的化複製―欠陥ビリオン
JP3034025B2 (ja) * 1989-06-01 2000-04-17 アプライド・バイオテクノロジー・インコーポレーテツド 自己アセンブルド欠損非自己増殖性ウイルス粒子
JP4041535B2 (ja) * 1989-08-18 2008-01-30 オックスフォード バイオメディカ（ユーケー）リミテッド 標的細胞にベクター構造体を運搬する組換レトロウィルス
ATE199398T1 (de) * 1989-10-24 2001-03-15 Chiron Corp Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen protein
EP0549723A1 (de) * 1990-09-21 1993-07-07 Chiron Corporation Verpackungs-zellen
JP3547129B2 (ja) * 1991-02-19 2004-07-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 変更宿主域を有するウィルス粒子

Also Published As

Publication number Publication date
JP3655307B2 (ja) 2005-06-02
EP0702717B1 (de) 2006-05-03
AU686181B2 (en) 1998-02-05
WO1994029440A1 (en) 1994-12-22
US5512421A (en) 1996-04-30
DE69434724T2 (de) 2007-05-10
AU7052394A (en) 1995-01-03
EP0702717A4 (de) 2000-04-05
DE69434724D1 (de) 2006-06-08
EP0702717A1 (de) 1996-03-27
JPH08511685A (ja) 1996-12-10
US5670354A (en) 1997-09-23

Similar Documents

Publication Publication Date Title
ATE325187T1 (de) Bildung, konzentration und effizienter transfer von vsv-g pseudotypisierten retroviralen vektoren
ATE208813T1 (de) Modifizierte zellen mit resistenz gegen retroviralinfektionen
DE69435316D1 (de) Verfahren zur herstellung von hohen virustitern und die hocheffiziente transduktion von säugerzellen durch retroviren
DE59911900D1 (de) Retrovirale, mit LCMV-Glykoprotein pseudotypisierte Hybrid-Vektoren
BG60107B2 (bg) Метод за получаване на еукариотен полипептид
BG49720A3 (en) Method for virus- resistable plants obtaining
WO1995006743A3 (en) Methods and compositions for the large scale production of recombinant adeno-associated virus
DK0500917T3 (da) Vacciner og fremgangsmåder baseret på rekombinante herpes simplex virusser.
GR3022850T3 (en) Synthetic DNA derived recombinant HIV-1 antigens
ATE67244T1 (de) Herstellung und reinigung von lymphokinen.
CA2410297A1 (en) Assembly of wild-type and chimeric influenza virus-like particles (vlps)
CA2295858A1 (en) Rhabdoviruses with reengineered coats
ZA968382B (en) Vector and method of use for nucleic acid delivery to non-dividing cells
DK355486A (da) Fusionsproteiner, deres fremstilling og anvendelse
ATE154363T1 (de) Synthetische polypeptide als inhibitoren von hiv- 1
RU94046212A (ru) Последовательности днк, плазмиды, способ применения плазмид, растения, бактерии, способ применения последовательностей, способ приготовления и трансформации дрожжевых штаммов, дрожжевые штаммы, способ применения дрожжевых штаммов
DK0632129T3 (da) Rekombinante foamy-virusvektorer til medicinsk og diagnostisk anvendelse, og fremgangsmåder til at præparere rekombinante foamy-virusvektorer
DE68914316D1 (de) Polypeptide aus Vipergift und deren Genexpression.
Suarez et al. Identification of hypervariable and conserved regions in the surface envelope gene in the bovine lentivirus
CA2019803A1 (en) Feline interferon and process for production thereof
CA2164324A1 (en) Generation concentration and efficient transfer of vsv-g pseudotyped retroviral vectors
DE69318716D1 (de) Anti-Katze Immundefiziensvirus (FIV) Impfstoffe
Hantula et al. Chemical crosslinking of bacteriophage φ6 nucleocapsid proteins
FR2600079B1 (fr) Vecteur viral et adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la proteine, proteine obtenue, vaccin et anticorps obtenus
DE3877136D1 (de) Rekombinantes histidinreiches protein von plasmodium falciparum, seine herstellung und verwendung.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties